HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (22) Citing Articles via Google Scholar Google Scholar Articles by Hanf, G. Articles by Kunkel, G. Search for Related Content PubMed PubMed Citation Articles by Hanf, G. Articles by Kunkel, G.

Omalizumab inhibits allergen challenge-induced nasal response

Allergy and Asthma Clinic, Charité, Humboldt University Berlin, Germany

CORRESPONDENCE: G. Kunkel, Allergy and Asthma Clinic Charité, Virchow Klinikum, Humboldt University, Augustenburger Platz 1, 13353, Berlin, Germany. Fax: 49 30450565902. E-mail: gerald.hanf@charite.de

Keywords: allergic rhinitis, anti-imunoglobulin-E, omalizumab, rhuMAb-E25

Received: December 4, 2001
Accepted September 8, 2003

Elevated serum levels of antigen-specific immunoglobulin (Ig)E are often associated with allergic respiratory diseases. This parallel-group, randomised, double-blind, placebo-controlled trial was designed to study the influence of omalizumab on the early nasal response to allergen challenge reflected by symptom score and inflammatory marker levels in nasal lavage fluid (NAL).

A total of 23 patients with allergic rhinitis took part in the study, 11 were given placebo and omalizumab was administered subcutaneously in 12. Omalizumab or placebo were given at 2- or 4-week intervals based on a patient's body weight and IgE levels to a total dose of 0.016 mg·kg^–1·IgE^–1 (IU·mL^–1) every 4 weeks.

Compared to placebo, 16 weeks of treatment with omalizumab significantly inhibited allergen challenge-induced nasal symptoms (median symptom score 7.0–0.5 versus 7.0–7.0) and inhibited the increase of human serum albumin (median 15.3–0.12 mg·mL^–1 versus 8.2–19.7 mg·mL^–1) in the NAL after allergen challenge. Treatment with omalizumab induced a significant decrease in tumour necrosis factor- levels in basal NAL, but no change was seen for histamine.

These results indicate that subcutaneously administered monoclonal anti-immunoglobulin-E antibody, omalizumab, inhibits the nasal responses to allergen challenge of patients with allergic rhinitis. Omalizumab may provide a new strategy for the treatment of allergic rhinitis.

This article has been cited by other articles:

				J. Bousquet, U. Wahn, E. O. Meltzer, H. Fox, S. Hedgecock, K. Thomas, and A. Fowler-Taylor Omalizumab: an anti-immunoglobulin E antibody for the treatment of allergic respiratory diseases Eur. Respir. Rev., April 1, 2008; 17(107): 1 - 9. [Abstract] [Full Text] [PDF]

				D.K.C. Lee The role of omalizumab or rhuMAb-E25 in the treatment of allergic rhinitis Eur. Respir. J., August 1, 2004; 24(2): 330 - 330. [Full Text] [PDF]

				G. Hanf and O. Noga From the Authors Eur. Respir. J., August 1, 2004; 24(2): 330 - 331. [Full Text] [PDF]